From drug pricing to reforming the drug regulatory process, Trump’s re-election has plenty of implications for the pharma ...

"The FDA's approval of Lumryz was not arbitrary or capricious," U.S. District Judge Amit P. Mehta wrote in a memorandum ...

Kennedy Jr. has said he will clear out "entire departments" of the U.S. Food and Drug Administration (FDA) if given a place ...

He has gotten large donations from and owns hundreds of thousands of dollars in stocks in drug and medical device companies.

Robert F. Kennedy Jr. may have a significant influence on public health matters following Donald Trump's presidential victory ...

Past comments by Robert F. Kennedy Jr. hint at the ideas he might advocate for if given a role in the incoming Trump ...

Sen. Baldwin says opponent Hovde “opposes efforts to negotiate with the big pharmaceutical companies to lower the price of ...

Pharmaceutical executives and public health experts have warned that Robert F Kennedy Jr’s influence over Donald Trump could ...

STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

NextCure is going all in on its preclinical B7-H4-directed antibody-drug conjugate (ADC). | NextCure is going all in on its ...

Cytokinetics launched its HCM Beyond the Heart effort to bring greater attention to the disease state and differentiate the ...